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Abstract
Background: The clinical benefit of cetuximab combined with oxaliplatin-based chemotherapy remains under
debate. The aim of the present multicenter open-label Phase II study was to explore the efficacy and safety of
biweekly administration of cetuximab and mFOLFOX-6 or XELOX as first-line chemotherapy in patients with
metastatic colorectal cancer.
Methods: Sixty-two patients with previously untreated KRAS/BRAF wild-type metastatic colorectal cancer were
recruited to the study between April 2010 and May 2011. Patients received one of two treatment regimens, either
cetuximab plus mFOLFOX-6 (FOLFOX + Cmab) or cetuximab plus biweekly XELOX (XELOX + Cmab), according to
their own preference. Treatment was continued until disease progression or the appearance of intolerable toxicities.
The primary endpoint was response rate; secondary endpoints were progression-free survival, overall survival,
disease control rate, dose intensity, conversion rate to surgical resection, and safety.
Results: The response rates in the FOLFOX + Cmab (n = 37) and XELOX + Cmab (n = 25) groups were 64.9 % (24/37)
and 72.0 % (18/25), respectively. The median PFS in the FOLFOX + Cmab and XELOX + Cmab groups was 13.1 months
(95 % confidence interval [CI] 12.1–17.5) and 13.4 months (95 % CI 10.1–17.9), respectively. Neutropenia was the most
frequent grade 3/4 adverse event in both groups (33.9 %), followed by anorexia, acneiform eruption, skin fissure and
paronychia. A waterfall plot of tumor diameter showed prominent shrinkage of the tumors in 88.7 % of patients.
Conclusions: The results of the present study indicate that biweekly cetuximab plus mFOLFOX-6/XELOX is an effective
and tolerable treatment regimen. Biweekly administration of cetuximab requires only one hospital visit every 2 weeks,
and may become a convenient treatment option for patients with KRAS/BRAF wild-type metastatic colorectal cancer.
Trial registration: This study is registered with University Hospital Medical Information Network (UMIN 000003253).
Registration date is 02/24/2010.
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Background
Cetuximab is a monoclonal antibody that targets the
extracellular domain of epidermal growth factor receptor
and modulates the proliferation of tumor cells. Cetuxi-
mab, in combination with irinotecan-based chemother-
apy or as monotherapy, prolongs the survival of patients
with metastatic colorectal cancers (mCRC) [1, 2]. How-
ever, clinical trials examining the benefit of adding
cetuximab to oxaliplatin-based regimens as first-line
therapy have reported inconsistent results. For example,
the Oxaliplatin and Cetuximab in First-Line Treatment
of Metastatic Colorectal Cancer (OPUS) study and sub-
sequent updates demonstrated a superior response rate
(RR) and progression-free survival (PFS), as well as
favorable overall survival (OS), in the cetuximab plus
FOFOX-4 group compared with FOLFOX-4 alone [3, 4].
Similarly, a retrospective pooled analysis of the Cetuxi-
mab Combined with Irinotecan in First-line Therapy for
Metastatic Colorectal Cancer (CRYSTAL) and OPUS
randomized clinical trials showed that adding cetuximab
to standard first-line chemotherapy (FOLFIRI and FOL-
FOX) had a significant survival benefit [5].
Conversely, the COIN trial, a large prospective study
investigating the potential benefit of adding cetuximab
to oxaliplatin-based therapy (FOLFOX and triweekly
XELOX) in v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog (KRAS) wild-type mCRC, failed to confirm any
additional beneficial effects [6]. However, there are sev-
eral concerns with that study, including a protocol
amendment to reduce the dose of capecitabine only in
the XELOX plus cetuximab group, a significantly smaller
dose intensity of oxaliplatin in the XELOX plus cetuxi-
mab group compared with the corresponding control
group [7], and significantly fewer patients receiving
second-line treatment in the combination therapy group
than in the chemotherapy alone group [6]. These differ-
ences that were generated during the trial may have
obscured the beneficial effects of combination therapy
on PFS and OS despite the better RR. Because of the
currently limited range of therapeutic treatments avail-
able for mCRC, we believe further studies are needed to
clarify whether the addition of cetuximab to oxaliplatin-
based chemotherapy will provide further benefits.
From another perspective, biweekly XELOX (without
molecular targeting therapy) has been reported to have
similar antitumor activity and safety profile to triweekly
XELOX [8, 9]. Likewise, the efficacy and safety of
biweekly cetuximab have been shown to be comparable
with those of the weekly regimen [10, 11]. In terms of
convenience for patients, a 2-week cycle of intravenous
oxaliplatin well matches biweekly administration of
cetuximab. Considering that curing metastatic colorectal
cancer remains difficult in most patients, in addition to
treatment efficacy, the safety and convenience of any
treatment modality are of considerable importance.
Thus, to determine the efficacy of the addition of
biweekly cetuximab, we undertook a Phase II trial of
biweekly cetuximab plus biweekly XELOX or mFOLFOX-
6 as first-line therapy for mCRC. On the basis of results
from the COIN trial, in which the dose of capecitabine
was reduced in the triweekly XELOX and cetuximab
group, the dose of capecitabine used in the present study




Patients with KRAS codon 12, 13, 61 wild-type meta-
static colorectal cancer who had not been treated previ-
ously with chemotherapy, with the exception of adjuvant
chemotherapy with oral fluoropyrimidines, were enrolled
in the present study. In addition, patients with BRAF
(V600E) mutation metastatic colorectal cancer (mCRC)
were excluded from the study because of the possible
relationships between the BRAF (V600E) mutation of
mCRC and a poor response to cetuximab treatment,
and/or the mutation and a poor prognosis [12–14].
Patients were eligible for inclusion if they were ≥20 years
of age, had histologically confirmed colorectal cancer, had
Eastern Cooperative Oncology Group (ECOG) perform-
ance status ≤1, had at least one radiologically measurable
lesion, had an estimated life expectancy of ≥3 months, and
had adequate function of their vital organs, including liver,
kidney and bone marrow. Patients with metastatic tumor
recurrence >24 weeks after adjuvant chemotherapy with
an oxaliplatin-base regimen were also eligible for inclusion
in this study.
Study design
This study was a single-arm Phase II open-label non-
randomized multi-institutional clinical trial investigating
the efficacy and safety of biweekly cetuximab plus either
mFOLFOX-6 (FOLFOX +Cmab) or biweekly XELOX
(XELOX+Cmab) as first-line therapy for metastatic colo-
rectal cancer. This study is registered with the University
Hospital Medical Information Network (UMIN) in Japan
(study ID: UMIN 000003253, Date: 02/24/2010). The
study was performed after approval by the Institutional
Ethics Review Board of Yamaguchi University (ID: H22-
13), as well as approval from relevant institutional review
boards (IRBs) from each of the participating institutes (see
Additional file 1), and was conducted in accordance with
the Declaration of Helsinki. Written informed consent
was obtained from each patient prior to their enrolment
in the study. Patients were recruited to the study between
April 2010 and May 2011, and one of two chemotherapy
regimens was chosen based on individual patient prefer-
ences (Fig. 1). On Day 1 of the 2-week treatment cycle,
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patients in both groups received cetuximab (500 mg/m2
over 2 h, followed by the same dose at a rate of <10 mg/
min thereafter). In the FOLFOX +Cmab group, the
mFOLFOX-6 regimen consisted of oxaliplatin 85 mg/m2
over 2 h, folinic acid 400 mg/m2 over 2 h, and bolus
administration of 5-fluorouracil (5-FU) 400 mg/m2 on
Day 1, followed by continuous infusion of 2400 mg/m2 5-
FU over 46 h. In the XELOX +Cmab group, the biweekly
XELOX regimen consisted of oxaliplatin 85 mg/m2 over
2 h on Day 1 and oral capecitabine 1000 mg/m2 twice
daily on Days 1–7. Both treatment regimens were contin-
ued until disease progression or the appearance of intoler-
able toxicity.
Physical examination and clinical data were collected
prospectively for analysis before each treatment cycle.
Adverse events were monitored and evaluated according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) version 4.0.
Criteria for continuation of treatment were: leuko-
cytes >3000 /mm3, neutrophils >1500 /mm3, throm-
bocytes >7.5 × 104 /mm3; alanine aminotransferase
(ALT), aspartate aminotransferase (AST), serum total
bilirubin and creatinine levels less than two times the
upper limit of normal (ULN); vomiting, nausea and
diarrhea less than grade 1; and hand–foot syndrome less
than grade 2 for chemotherapy. Additional criteria for
continuation of treatment included serum magnesium
levels >0.7 mg/dL and cetuximab-related dermatological
adverse events less than grade 2. When there was a delay
in treatment of >14 days, treatment according to the study
protocol was discontinued.
The primary endpoint of the present study was object-
ive RR assessed using the Response Evaluation Criteria
in Solid Tumors (RESIST) version 1.1 [15]. Tumors were
evaluated by computed tomography immediately before
initiation of treatment (within 2 weeks), 4 weeks after
the initial treatment, and then at <8-weekly intervals
thereafter. Secondary endpoints included PFS, OS, dis-
ease control rate (DCR), conversion rate to curative sur-
gery for liver metastasis, dose intensity (DI), response
rate of each metastatic site, and safety.
Dose modification
Criteria for a dose reduction of oxaliplatin or fluoropyri-
midines included grade 4 leukopenia and neutropenia,
grade 3/4 thrombocytopenia, grade 3 febrile neutropenia,
grade 3/4 nausea, vomiting, diarrhea, anorexia and stoma-
titis. In the case of Grade 2 peripheral neuropathy, the
oxaliplatin dose was reduced. In the case of grade 3/4
acne-like rash and hand–foot syndrome, doses of cetuxi-
mab and capecitabine were reduced, respectively. When a
grade 1 or 2 infusion reaction to oxaliplatin or cetuximab
was observed, the infusion rate was reduced to <20 mg/
min. For grade 3 or 4 infusion reactions, treatment ac-
cording to the study protocol was discontinued. First and
second dose reductions were by approximately 20 % and
40 % of the initial dose, respectively. When adverse events
necessitating further dose reductions occurred, treatment
according to the study protocol was discontinued.
KRAS and BRAF mutations
DNA was extracted from formalin-fixed, paraffin-
embedded tumor tissues. Mutations of KRAS at codons
12, 13, and 61 and BRAF mutations at codon 600 were
detected by direct sequencing, as described previously
[16, 17].
Fig. 1 Disposition of patients. In all, 139 patients were analyzed for KRAS and BRAF mutation status. Of these, 70 patients (50.4 %) had both KRAS
and BRAF wild-type metastatic colorectal cancer, and 62 fulfilled the inclusion criteria for the study. Of the 62 patients enrolled in the study, 37
chose to receive mFOLFOX-6 plus cetuximab treatment (FOLFOX + Cmab), whereas 25 chose XELOX plus cetuximab treatment (XELOX + Cmab)
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Statistical analysis
>Statistical analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA). The target sample size
of 57 (52 eligible patients and 10 % ineligible patients) was
based on expected and threshold response rates of 62 and
40 %, respectively, with α = 0.05 and β = 0.1. P < 0.05 was
considered significant. Graphs were created using Kaleida-
Graph version 4.0 (Synergy Software, Reading, PA, USA),
Photoshop CS2 (Adobe Systems, San Jose, CA, USA) and
IBM SPSS Statistics 19 (IBM, Armonk, NY, USA).
Results
Patient recruitment and characteristics
Between April 2010 and May 2011, 139 patients from 34
institutions were provisionally registered as candidates for
this study (Fig. 1). Analysis of KRAS and BRAF mutations
identified 69 cases of KRAS or BRAF mutations, most of
which were observed at codons 12 and 13 of KRAS (38
and 25 cases, respectively). Mutations of codon 61 were
identified in two patients only, whereas four patients were
found to have BRAF (V600E) mutations.
Seventy patients (50.4 %) had both KRAS and BRAF
wild-type metastatic colorectal cancer, and 62 patients
fulfilled the inclusion criteria (45.2 % [28/62] female;
median age 66 years [range 34–83 years]; Table 1) and
were enrolled in the present study. Of these, 37 patients
were treated with the mFOLFOX-6 plus cetuximab regi-
men (FOLFOX + Cmab group), whereas 25 patients
chose XELOX plus cetuximab treatment (XELOX +
Cmab group). The liver was the most common site of
metastasis (n = 47; 75.8 %) and one patient had metasta-
ses to more than one site.
Treatment efficacy
Overall, two complete and 40 partial responses were
observed (Table 2), and the RR for both groups was
67.7 %. Because 15 patients (24.2 %) had stable disease,
the DCR was 91.9 %. There was no significant difference
in the response rate between the FOLFOX + Cmab and
XELOX + Cmab groups (64.9 % vs 72.0 %, respectively;
P = 0.56, Chi-squared test). The median PFS in the FOL-
FOX+Cmab and XELOX+Cmab groups was 13.1 months
(95 % confidence interval [CI] 11.4–18.3) and 13.4 months
(95 % CI 10.1–17.9), respectively (Fig. 2). Furthermore,
88.7 % of patients exhibited prominent tumor shrinkage
during treatment (Fig. 3). When response rate was assessed
in patients with only one metastatic site, the response rates
for liver, lung and lymph node metastases were 71.4 % (20/
28), 75 % (3/4), and 57.1 % (4/7), respectively. At the final
assessment, after a median follow-up of 36.3 months (95 %
CI 28.4–35.6), 54.8 % of patients (34/62) had died: 88 % of
the deaths were due to disease progression, and 6.5 % of
patients (4/62) died of other causes, including pneu-
monia and unexpected accidents. The median OS in
the FOLFOX + Cmab and XELOX + Cmab groups was
38.1 months (95 % CI 33.5–42.6) and 47.0 months
(95 % CI 32.1–61.9), respectively.
Exposure to treatment
The median number of treatment cycles was 10 (Table 3).
The median cumulative dose of cetuximab was 6480 mg/
m2 and the DI was 216 mg/m2 per week. Fifty-two of 62
patients received a relative DI >75 %. In the case of oxali-
platin, 37 of 62 patients received a relative DI >75 %.
There was no significant difference in the DI of oxaliplatin
Table 1 Characteristics of patients with KRAS and BRAF wild-type metastatic colorectal cancer treated with either mFOLFOX-6 plus
cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)
All patients (n = 62) FOLFOX + Cmab (n = 37) XELOX + Cmab (n = 25) P-value
No. women 28 (45.2 %) 18 (48.9 %) 10 (40.0 %) 0.502
Median (range) age (years) 66 (34–83) 67 (45–83) 66 (34–83) 0.769
ECOG performance status 0.885
0 55 (88.7 %) 33 (89.2 %) 22 (88.0 %)
1 7 (11.3 %) 4 (10.8 %) 3 (12.0 %)
Primary tumor site 0.193
Colon 36 (58.1 %) 18 (48.6 %) 8 (32.0 %)
Rectum 26 (41.9 %) 19 (51.4 %) 17 (68.0 %)
Metastatic site
Liver 47 (75.8 %) 29 (78.4 %) 18 (72.0 %) 0.136
Lymph node 18 (29.0 %) 13 (35.1 %) 5 (20.0 %)
Lung 15 (24.2 %) 10 (27.0 %) 5 (20.0 %)
Other 8 (12.9 %) 2 (5.4 %) 6 (24.0 %)
Unless indicated otherwise, data show the number of patients in each group, with percentage in parentheses
ECOG Eastern Cooperative Oncology Group
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between the FOLFOX +Cmab and XELOX +Cmab
groups (P = 0.25, t-test).
Seventeen patients (27.4 %) discontinued treatment
because of disease progression, whereas 19 patients
(30.6 %) discontinued the study treatment protocol to
undergo surgical resection. In nine patients (14.5 %),
there was an unacceptable delay in treatment (>14 days)
after a median treatment period of 5 months. One
patient in the FOLFOX + Cmab group developed
interstitial pneumonia, although it is not clear whether
this was related to the treatment regimen.
Safety and adverse events
Common adverse events are shown in Fig. 4 (see
Additional file 2 for more information). Across the
entire patient cohort, the most common grade 3 and
grade 4 adverse event was neutropenia, followed by
acneiform eruption and paronychia. The skin
Table 2 Efficacy of treatment with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab)
All patients (n = 62) FOLFOX + Cmab (n = 37) XELOX + Cmab (n = 25)
Tumor response
CR 2 2 0
PR 40 22 18
SD 15 9 6
PD 3 2 1
NE 2 2 0
Response rate (%) 67.7 (54.7–79.1) 64.9 (47.5–79.8) 72.0 (50.6–87.9)
DCR (%) 91.9 (82.3–97.3) 89.2 (74.6–97.0) 96.0 (79.7–99.9)
Median PFS (months) 13.4 (12.1–17.5) 13.1 (11.4–18.3) 13.4 (10.1–17.9)
Median OS (months) 38.1 (30.3–45.8) 38.1 (33.5–42.6) 47.0 (32.1–61.9)
Data are given as the number of patients in each group or as median values with 95 % confidence intervals in parentheses
CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, DCR disease control rate, PFS progression free survival; OS,
overall survival
Fig. 2 Progression-free survival (PFS). PFS is shown for patients treated with mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab
(XELOX + Cmab). A log-rank test did not reveal any significant differences in PFS between the two groups (P = 0.99)
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Fig. 3 Maximum change in tumor size from baseline in individual patients over the course of treatment. Changes in tumor size (diameter) were
assessed in patients treated with mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab). Tumor shrinkage relative
to baseline was observed in 88.7 % of patients, revealing the strength of combination therapy with cetuximab and oxaliplatin-based chemotherapy
Table 3 Exposure to treatment for patients treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus
cetuximab (XELOX + Cmab)
All (n = 62) FOLFOX + Cmab (n = 37) XELOX + Cmab (n = 25)
No. treatment cycles
Median 10 (5.5–17.5) 10 (5–19) 9.5 (6–14)
Cetuximab treatment
Cumulative dose (mg/m2) 6480 (2187–12 480) 6750 (3580–14 634) 6397 (4302–11 198)
DI (mg/m2 per week) 216 (189–247) 223 (189–233) 237 (179–261)
No. with relative DI >75 % 52 28 24
Oxaliplatin
Cumulative dose (mg/m2) 992 (600–1812) 987 (505–2021) 1008 (661–1597)
DI (mg/m2 per week) 31.4 (24–39) 30 (28–35) 39 (29–42)
No. with relative DI >75 % 37 20 17
Bolus 5-FU
Cumulative dose (mg/m2) 4392 (1795–9928)
DI (mg/m2 per week) 135 (120–175)
No. with relative DI >75 % 21
5-FU Infusion
Cumulative dose (mg/m2) 28414 (14750–60644)
DI (mg/m2 per week) 890 (803–1062)
No. with relative DI >75 % 21
Capecitabine
Cumulative dose (mg/m2) 23700 (14250–38925)
DI (mg/m2 per week) 878 (666–978)
No. with relative DI >75 % 16
Numbers in parenthesis show the interquartile range
DI dose intensity, 5-FU 5-fluorouraci
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eruptions related to cetuximab administration oc-
curred at a similar rate in both groups. Grade 4 neutro-
penia was observed in both the FOLFOX+Cmab and
XELOX +Cmab groups, whereas hand–foot syndrome
was seen only in the XELOX+Cmab group. No patient
died within 28 days of the last treatment cycle.
Discussion
The present Phase II study has demonstrated the treat-
ment efficacy and safety of biweekly cetuximab plus
oxaliplatin-based chemotherapy in patients with both
KRAS and BRAF wild-type mCRCr. The RR to treatment
in the FOLFOX + Cmab and XELOX + Cmab groups
was 64.9 % and 72.0 %, respectively. A waterfall plot
showed substantial tumor shrinkage in most patients in
both groups. The treatment was well tolerated, allowing
a median treatment duration of 5.4 months, which cor-
responds to a median number of 10 treatment cycles.
Several clinical trials have demonstrated that the over-
all RR (or RR) to FOLFOX plus weekly cetuximab treat-
ment varies between 57 and 72 % [3, 18–20] . Thus, the
RR obtained in the present study is within the range
reported previously. Furthermore, biweekly adminis-
tration of cetuximab and FOLFOX was recently re-
ported to have a similar RR [21, 22], which suggests
that biweekly administration of cetuximab in combin-
ation with FOLFOX is an acceptable treatment op-
tion, and that the biological response of the tumor to
this treatment regimen is similar in different studies,
including the present clinical study.
In the present study, the RR to biweekly cetuximab
and XELOX was 70.2 %. To our knowledge, the clinical
efficacy of XELOX and cetuximab has only been
reported in a few studies up until now. For example, a
Swiss study reported a RR of 45.6 % to XELOX and
weekly cetuximab treatment, administered regardless of
the KRAS mutation status [23]. In the COIN trial, the
overall RR to XELOX combination therapy was 51 %
in patients with KRAS wild-type mCRC [18]. These
results may have been interpreted to mean that the
addition of cetuximab to XELOX is less advantageous
than FOLFOX treatment. However, in the present
study, an equivalent or even higher RR was obtained
in the XELOX + Cmab group compared with the
FOLFOX + Cmab group. Even though direct compari-
sons of trial results can be challenging, we consider
that the findings of the present study are important
because they are derived from proper dosage adjust-
ment of capecitabine and a biweekly cycle of infusion
treatment that was accompanied by pre-treatment
physical and laboratory assessments.
The dose of capecitabine used in the present study
was determined on the basis of results from a previous
trial. In the COIN trial, patients were initially adminis-
tered 1000 mg/m2 capecitabine twice daily for 2 weeks
as part of a triweekly XELOX regimen [6]. After 73 % of
all patients had been randomized, the dose of capecita-
bine was reduced to 850 mg/m2 twice daily only in the
cetuximab plus XELOX treatment arm due to a higher
rate of adverse events than expected. Before this proto-
col amendment, patients in the XELOX plus cetuximab
treatment group received significantly lower doses of
both oxaliplatin and capecitabine compared with the
corresponding control group [6, 7], which could have
Fig. 4 Common adverse events. Common adverse events in patients treated with either mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus
cetuximab (XELOX + Cmab) are shown. The percentages of grade III or IV adverse events for both treatments are shown. The figures in parenthesis are
the percentages of grade I or II adverse events
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obscured the benefit of combination therapy in the
COIN trial. Thus, in the present study, the dose of cape-
citabine was set at 1000 mg/m2 twice daily for 1 week as
part of the biweekly XELOX regimen, which is compar-
able to the reduced DI in the COIN trial (1000 vs.
1133 mg/m2 per day). Consequently, the safety profile in
the XELOX + Cmab group was similar to that in the
FOLFOX + Cmab group, most likely contributing to the
continuation of treatment according to the study proto-
col and the achievement of higher RR in this study. In
addition, these positive effects could explain the longer
PFS in the present study compared with that reported in
the COIN trial (13.4 vs. 7.4 months, respectively). The
frequent use of second-line treatment in the present
study, including chemotherapy (43.5 %), radiation ther-
apy (6.5 %), and surgical resection (30.6 %), should also
be taken into account. In the COIN trial, only 56 % of
patients received second-line treatment, probably due to
frequent adverse events. These results may have some
effect on survival, and again highlight the importance of
proper dose adjustment.
The median OS in the present study was 38.1 months
(95 % CI 30.1–45.8). Based on the fact that 30.6 % of
patients underwent surgical resection a median of
3.75 months (95 % CI 2.96–4.14) after entering the
study, the patients in this study can be considered to be
in a relatively early phase of advanced disease. In view of a
recent report that median OS after hepatic resection for
metastatic colorectal cancer exceeds 45 months [24], the
results of the present study are within the expected range.
Indeed, the median OS for patients who underwent surgi-
cal resection was 47.7 months (95 % CI 40.3–55.1). More-
over, the results of the present study are encouraging
because the treatment regimens were found to be safe
pre-operative chemotherapy regimens for liver metastasis.
However, further studies in a larger number of patients
are needed to confirm this.
The occurrence of hand–foot syndrome, a characteris-
tic adverse event associated with the use of capecitabine,
was well controlled in this study. In the present study,
only two patients (of 25; 8.0 %) developed grade 3
hand–foot syndrome, which is lower than reported in
the COIN trial (13 %), but equivalent to that reported
for XELOX treatment alone [25]. Because several factors
(e.g. DI, patient characteristics etc.) often differ among
clinical trials, it is difficult to provide a definitive explan-
ation for the apparent differences in results. However,
the biweekly regimen generally allows for more frequent
physical assessment and the provision of prophylactic
information and/or treatment of any dermatological side
effects than triweekly regimen. Consequently, the pa-
tients in the present study could have received better
skin care, leading to less frequent adverse dermatological
events. One concern is that grade 3/4 neutropenia
occurred in as many as 40 % of patients in the XELOX
+ Cmab group, compared with a reported percentage of
grade 3/4 neutropenia in triweekly and/or biweekly
XELOX regimens between 3 and 10 % [6, 8, 9, 23, 25].
However, some studies in Japanese patients with colo-
rectal cancer have also reported a high rate of grade 3/4
neutropenia with XELOX-based regimens (16–20 %)
[26, 27]. Thus, differences in genetic background could
explain, in part, the different adverse event profiles in
Japanese patients.
One important limitation of the present study is the
lack of information regarding NRAS mutation status.
Recent retrospective studies analyzing samples from pro-
spective clinical trials, most of which were published
after the initiation of the present Phase II study, have re-
ported that mutations at NRAS codons 12, 13 and 61
have a negative effect on anti-EGFR antibody therapy in
mCRC patients [28, 29]. Although the rate of NRAS mu-
tations in mCRC in the Japanese population is not well
known, based on evidence from European countries we
would expect the rate to be approximately 5–10 %.
The exclusion of these patients from the present
study could have demonstrated a more evident effect
of the treatment regimen and robust results. Thus,
further studies taking NRAS mutation status into con-
sideration are necessary.
Conclusions
A Phase II study was conducted to explore the safety
and efficacy of biweekly administration of cetuximab
combined with mFOLFOX-6 or biweekly XELOX in pa-
tients with KRAS codon 12, 13, 61 wild-type and BRAF
(V600E) wild-type mCRC. Despite the small number of
patients recruited to the study and the strict selection
criteria, the results suggest that the treatment regimens
evaluated herein exhibit similar efficacy to established
treatment regimens, and have an acceptable safety pro-
file. In particular, the findings of the present study are
important in that we demonstrate that the combination
of a biweekly cycle of XELOX plus cetuximab resulted
in quite a high RR because of appropriate dose adjust-
ment and more frequent evaluation for and treatment of
adverse skin effects. Further studies comparing the treat-
ment efficacy of mFOLFOX-6 plus cetuximab with that
of a biweekly XELOX plus cetuximab regimen, focusing
on OS and ideally randomized in nature, are warranted
in order to establish optimal treatment strategies.
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